Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

ClinicalTrials.gov ID: NCT01420679

Public ClinicalTrials.gov record NCT01420679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients Previously Undiagnosed Peripheral T-cell Lymphoma Who Achieved an Objective Response After Initial Treatment With CHOP-based Chemotherapy

Study identification

NCT ID: NCT01420679
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Enrollment: 21 participants

Conditions and interventions

Conditions

Peripheral T-cell Lymphoma

Interventions

Pralatrexate Injection Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2011
Primary completion: Nov 30, 2017
Completion: Nov 30, 2017
Last update posted: Nov 18, 2021

2011 – 2017

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Detroit Clinical Research Center, PC	Novi	Michigan	48377	—
New York Presbyterian Hospital	New York	New York	10021	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01420679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 18, 2021 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01420679 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →